---
document_datetime: 2025-12-02 05:46:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/neoatricon.html
document_name: neoatricon.html
version: success
processing_time: 0.1055434
conversion_datetime: 2025-12-24 17:53:56.202093
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Neoatricon

[RSS](/en/individual-human-medicine.xml/240141)

##### Authorised

This medicine is authorised for use in the European Union

dopamine hydrochloride Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Neoatricon](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Neoatricon is used to treat hypotension (low blood pressure) in newborn babies, infants and children less than 18 years of age who have unstable blood pressure.

Neoatricon contains the active substance dopamine hydrochloride and is a hybrid medicine. This means that it is similar to a reference medicine containing the same active substance, but there are certain differences between the two.

Unlike the reference medicine (Sterile Dopamine Concentrate BP 40mg/mL, Ireland), Neoatricon is used in children and its strength and what it is used for are different from those of the reference medicine.

Expand section

Collapse section

## How is Neoatricon used?

Neoatricon is given as an infusion (drip into a vein) in a large vein under the supervision of a doctor. In newborns, the medicine may also be given into the umbilical cord. The amount of Neoatricon the patient receives depends on how they respond to treatment.

The medicine can only be obtained with a prescription. For more information about using Neoatricon, see the package leaflet or contact your healthcare provider.

## How does Neoatricon work?

Neoatricon contains the active substance dopamine hydrochloride. It works mainly by attaching to specific receptors (targets) called adrenergic receptors. Attaching to these receptors causes blood vessels to become more narrow and the heart to beat harder, thereby increasing blood pressure.

## What benefits of Neoatricon have been shown in studies?

The main benefits of dopamine have been shown in published studies. The studies showed that dopamine leads to an increase in arterial blood pressure, which helps to improve the blood supply to the organs of newborns, infants and children who have severe problems with their blood circulation.

## What are the risks associated with Neoatricon?

For the full list of side effects and restrictions with Neoatricon, see the package leaflet.

The most common side effects with Neoatricon (which may affect up to 1 in 10 people) include headache, problems with heart rhythm and electrical conduction in the heart, high blood pressure, piloerection (goosebumps), azotaemia (increased levels of nitrogen and other waste products in the blood), skin necrosis (death of skin tissue) and gangrene (decay and death of tissue)

## Why is Neoatricon authorised in the EU?

There is evidence from the published literature about the use of dopamine to increase blood pressure in children whose blood pressure is unstable. Important side effects include problems with the heart rhythm and reduced blood flow to tissues. The European Medicines Agency concluded that Neoatricon's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Neoatricon?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Neoatricon have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Neoatricon are continuously monitored. Suspected side effects reported with Neoatricon are carefully evaluated and any necessary action taken to protect patients.

## Other information about Neoatricon

Neoatricon received a marketing authorisation valid throughout the EU on 27 May 2024.

Neoatricon : EPAR - Medicine overview

Reference Number: EMA/181469/2024

English (EN) (148.73 KB - PDF)

**First published:** 19/06/2024

[View](/en/documents/overview/neoatricon-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-97)

български (BG) (150.04 KB - PDF)

**First published:**

19/06/2024

[View](/bg/documents/overview/neoatricon-epar-medicine-overview_bg.pdf)

español (ES) (126.75 KB - PDF)

**First published:**

19/06/2024

[View](/es/documents/overview/neoatricon-epar-medicine-overview_es.pdf)

čeština (CS) (146.8 KB - PDF)

**First published:**

19/06/2024

[View](/cs/documents/overview/neoatricon-epar-medicine-overview_cs.pdf)

dansk (DA) (125.51 KB - PDF)

**First published:**

19/06/2024

[View](/da/documents/overview/neoatricon-epar-medicine-overview_da.pdf)

Deutsch (DE) (129.22 KB - PDF)

**First published:**

19/06/2024

[View](/de/documents/overview/neoatricon-epar-medicine-overview_de.pdf)

eesti keel (ET) (124.98 KB - PDF)

**First published:**

19/06/2024

[View](/et/documents/overview/neoatricon-epar-medicine-overview_et.pdf)

ελληνικά (EL) (150.66 KB - PDF)

**First published:**

19/06/2024

[View](/el/documents/overview/neoatricon-epar-medicine-overview_el.pdf)

français (FR) (128.52 KB - PDF)

**First published:**

19/06/2024

[View](/fr/documents/overview/neoatricon-epar-medicine-overview_fr.pdf)

hrvatski (HR) (145.36 KB - PDF)

**First published:**

19/06/2024

[View](/hr/documents/overview/neoatricon-epar-medicine-overview_hr.pdf)

italiano (IT) (125.68 KB - PDF)

**First published:**

19/06/2024

[View](/it/documents/overview/neoatricon-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (176.24 KB - PDF)

**First published:**

19/06/2024

[View](/lv/documents/overview/neoatricon-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (146.56 KB - PDF)

**First published:**

19/06/2024

[View](/lt/documents/overview/neoatricon-epar-medicine-overview_lt.pdf)

magyar (HU) (145.94 KB - PDF)

**First published:**

19/06/2024

[View](/hu/documents/overview/neoatricon-epar-medicine-overview_hu.pdf)

Malti (MT) (149.9 KB - PDF)

**First published:**

19/06/2024

[View](/mt/documents/overview/neoatricon-epar-medicine-overview_mt.pdf)

Nederlands (NL) (126 KB - PDF)

**First published:**

19/06/2024

[View](/nl/documents/overview/neoatricon-epar-medicine-overview_nl.pdf)

polski (PL) (149.9 KB - PDF)

**First published:**

19/06/2024

[View](/pl/documents/overview/neoatricon-epar-medicine-overview_pl.pdf)

português (PT) (127.26 KB - PDF)

**First published:**

19/06/2024

[View](/pt/documents/overview/neoatricon-epar-medicine-overview_pt.pdf)

română (RO) (153.55 KB - PDF)

**First published:**

19/06/2024

[View](/ro/documents/overview/neoatricon-epar-medicine-overview_ro.pdf)

slovenčina (SK) (147.6 KB - PDF)

**First published:**

19/06/2024

[View](/sk/documents/overview/neoatricon-epar-medicine-overview_sk.pdf)

slovenščina (SL) (145 KB - PDF)

**First published:**

19/06/2024

[View](/sl/documents/overview/neoatricon-epar-medicine-overview_sl.pdf)

Suomi (FI) (124.29 KB - PDF)

**First published:**

19/06/2024

[View](/fi/documents/overview/neoatricon-epar-medicine-overview_fi.pdf)

svenska (SV) (124.93 KB - PDF)

**First published:**

19/06/2024

[View](/sv/documents/overview/neoatricon-epar-medicine-overview_sv.pdf)

Neoatricon : EPAR - Risk management plan

English (EN) (1.18 MB - PDF)

**First published:** 19/06/2024

[View](/en/documents/rmp/neoatricon-epar-risk-management-plan_en.pdf)

## Product information

Neoatricon : EPAR - Product information

English (EN) (474.66 KB - PDF)

**First published:** 19/06/2024

**Last updated:** 04/07/2025

[View](/en/documents/product-information/neoatricon-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-415)

български (BG) (583.19 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/bg/documents/product-information/neoatricon-epar-product-information_bg.pdf)

español (ES) (498.62 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/es/documents/product-information/neoatricon-epar-product-information_es.pdf)

čeština (CS) (558.63 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/cs/documents/product-information/neoatricon-epar-product-information_cs.pdf)

dansk (DA) (498.61 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/da/documents/product-information/neoatricon-epar-product-information_da.pdf)

Deutsch (DE) (519.69 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/de/documents/product-information/neoatricon-epar-product-information_de.pdf)

eesti keel (ET) (492.47 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/et/documents/product-information/neoatricon-epar-product-information_et.pdf)

ελληνικά (EL) (581.42 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/el/documents/product-information/neoatricon-epar-product-information_el.pdf)

français (FR) (516.17 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/fr/documents/product-information/neoatricon-epar-product-information_fr.pdf)

hrvatski (HR) (555.85 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/hr/documents/product-information/neoatricon-epar-product-information_hr.pdf)

íslenska (IS) (492.82 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/is/documents/product-information/neoatricon-epar-product-information_is.pdf)

italiano (IT) (498.57 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/it/documents/product-information/neoatricon-epar-product-information_it.pdf)

latviešu valoda (LV) (552.74 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/lv/documents/product-information/neoatricon-epar-product-information_lv.pdf)

lietuvių kalba (LT) (573.12 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/lt/documents/product-information/neoatricon-epar-product-information_lt.pdf)

magyar (HU) (600.28 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/hu/documents/product-information/neoatricon-epar-product-information_hu.pdf)

Malti (MT) (628.21 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/mt/documents/product-information/neoatricon-epar-product-information_mt.pdf)

Nederlands (NL) (505.49 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/nl/documents/product-information/neoatricon-epar-product-information_nl.pdf)

norsk (NO) (480.6 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/no/documents/product-information/neoatricon-epar-product-information_no.pdf)

polski (PL) (573.12 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/pl/documents/product-information/neoatricon-epar-product-information_pl.pdf)

português (PT) (497.28 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/pt/documents/product-information/neoatricon-epar-product-information_pt.pdf)

română (RO) (569.28 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/ro/documents/product-information/neoatricon-epar-product-information_ro.pdf)

slovenčina (SK) (551.03 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/sk/documents/product-information/neoatricon-epar-product-information_sk.pdf)

slovenščina (SL) (554.02 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/sl/documents/product-information/neoatricon-epar-product-information_sl.pdf)

Suomi (FI) (487.96 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/fi/documents/product-information/neoatricon-epar-product-information_fi.pdf)

svenska (SV) (486.3 KB - PDF)

**First published:**

19/06/2024

**Last updated:**

04/07/2025

[View](/sv/documents/product-information/neoatricon-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000279197 27/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Neoatricon : EPAR - All authorised presentations

English (EN) (50.06 KB - PDF)

**First published:** 19/06/2024

[View](/en/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-416)

български (BG) (59.69 KB - PDF)

**First published:**

19/06/2024

[View](/bg/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_bg.pdf)

español (ES) (50.49 KB - PDF)

**First published:**

19/06/2024

[View](/es/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_es.pdf)

čeština (CS) (66.52 KB - PDF)

**First published:**

19/06/2024

[View](/cs/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (51.91 KB - PDF)

**First published:**

19/06/2024

[View](/da/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (52.19 KB - PDF)

**First published:**

19/06/2024

[View](/de/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (48.92 KB - PDF)

**First published:**

19/06/2024

[View](/et/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (66.02 KB - PDF)

**First published:**

19/06/2024

[View](/el/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_el.pdf)

français (FR) (50.31 KB - PDF)

**First published:**

19/06/2024

[View](/fr/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (68.56 KB - PDF)

**First published:**

19/06/2024

[View](/hr/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (54.23 KB - PDF)

**First published:**

19/06/2024

[View](/is/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_is.pdf)

italiano (IT) (49.98 KB - PDF)

**First published:**

19/06/2024

[View](/it/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (68.91 KB - PDF)

**First published:**

19/06/2024

[View](/lv/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (67.59 KB - PDF)

**First published:**

19/06/2024

[View](/lt/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (59.94 KB - PDF)

**First published:**

19/06/2024

[View](/hu/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (69.48 KB - PDF)

**First published:**

19/06/2024

[View](/mt/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (50.82 KB - PDF)

**First published:**

19/06/2024

[View](/nl/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (54.66 KB - PDF)

**First published:**

19/06/2024

[View](/no/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_no.pdf)

polski (PL) (70.49 KB - PDF)

**First published:**

19/06/2024

[View](/pl/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_pl.pdf)

português (PT) (51.81 KB - PDF)

**First published:**

19/06/2024

[View](/pt/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_pt.pdf)

română (RO) (67.53 KB - PDF)

**First published:**

19/06/2024

[View](/ro/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (68.77 KB - PDF)

**First published:**

19/06/2024

[View](/sk/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (58.93 KB - PDF)

**First published:**

19/06/2024

[View](/sl/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (49.17 KB - PDF)

**First published:**

19/06/2024

[View](/fi/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (50.41 KB - PDF)

**First published:**

19/06/2024

[View](/sv/documents/all-authorised-presentations/neoatricon-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Neoatricon Active substance

- dopamine hydrochloride
- Dopamine

International non-proprietary name (INN) or common name dopamine hydrochloride Therapeutic area (MeSH) Hypotension Anatomical therapeutic chemical (ATC) code C01CA04

### Pharmacotherapeutic group

Cardiac therapy

### Therapeutic indication

Treatment of hypotension in haemodynamically unstable neonates, infants and children &lt; 18 years

## Authorisation details

EMA product number EMEA/H/C/006044 Marketing authorisation holder

BrePco Biopharma Limited

Suite 1 The Avenue Beacon Court Sandyford Dublin 18 IRELAND

Opinion adopted 21/03/2024 Marketing authorisation issued 27/05/2024 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Neoatricon : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (134.1 KB - PDF)

**First published:** 04/07/2025

[View](/en/documents/procedural-steps-after/neoatricon-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Neoatricon : EPAR - Public assessment report

Adopted

Reference Number: EMA/260885/2024

English (EN) (3.46 MB - PDF)

**First published:** 19/06/2024

[View](/en/documents/assessment-report/neoatricon-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Neoatricon

Adopted

Reference Number: EMA/CHMP/61250/2024

English (EN) (94.03 KB - PDF)

**First published:** 22/03/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-neoatricon_en.pdf)

#### News on Neoatricon

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024) 22/03/2024

**This page was last updated on** 04/07/2025

## Share this page

[Back to top](#main-content)